Adam Teitcher represents clients in complex commercial cases and government enforcement actions in federal and state courts across the country. With a focus on the pharmaceutical, life sciences, and healthcare industries, Adam’s practice spans a broad range of civil and commercial matters including mass torts, product liability, consumer protection, unfair business practices, fraud, and public nuisance, as well as retail, financial services, and technology. Adam counsels clients through all aspects of litigation from pre-litigation investigations through trial and appeal. As trial counsel, he has experience with and achieved victories in some of the largest and most complex cases in recent history.
Adam has a proven ability to manage, motivate, and lead teams in high-pressure and complex matters. Most recently, Adam served as trial counsel for one of the world’s largest manufacturers of generic pharmaceutical products and obtained a complete defense victory in the national opioid litigation in Orange County, California Superior Court. The trial, which was the culmination of seven years of litigation, lasted more than four months and secured the first trial defense win in the national opioid litigation. Adam built the case leading up to trial and was critical in developing and implementing case and trial strategy. Adam has since served as trial counsel in other opioid litigation trials across the country, including in Rhode Island and San Francisco. The Rhode Island trial settled just as opening statements were to begin, and the San Francisco trial settled just before closing arguments, after more than two months of trial.
Adam maintains an active pro bono practice, covering election and voting rights, immigration, and civil rights.
Listed, The Best Lawyers in America, Ones to Watch, Commercial Litigation, Costa Mesa (2023–2025)
Recommended, Dispute resolution: Product liability, mass tort and class action - defense: pharmaceuticals and medical devices, The Legal 500 US (2022–2024)
Associate Editor, Fordham Law Review, Vol. 80.